VLP Biotech
UEI: JPNRGENTXC35
• CAGE: 4AX99
Overview
Awardee Type
Parent
Federal Capability Statement
VLP Biotech development of epitope-focused vaccines. Our technology enables elicitation of robust antibody and CD4 T cell responses to defined protein regions. Our technology is suited for carbohydrate or other target conjugation.
Keywords
Epitope-Focused Vaccine Virus-like Particle
SBA Special Equipment
Our virus-like particle platform is expressed in E. coli and self-assembles into a highly-stable, immunogenic particle.
Headquarters
San Diego, CA
United States
United States
Most Recent Award
May 1, 2019
Calculating
Federal grant recipient
VLP BIOTECH, INC.
(UEI JPNRGENTXC35, CAGE 4AX99)
is headquartered in San Diego CA.
Its primary registered NAICS is 541713 Research and Development in Nanotechnology.
The corporation
was founded in October 2003 and
federally registered in
February 2006.
Federal Award Analysis
VLP Biotech federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
VLP BIOTECH, INC.
UEI
JPNRGENTXC35
CAGE Code
4AX99
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Oct. 17, 2003
Initial Registration
Feb. 10, 2006
Last Registration
Jan. 29, 2025
Registration Activation
Jan. 29, 2025
Registration Expiration
Jan. 27, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
CA
Country of Incorporation
USA
Employees
<500
Reported NAICS
Accepts Credit Cards
No